INFINITY Phase 2 Trial for DME Patients

The INFINITY Phase 2 trial is a randomized, active comparator-controlled trial evaluating a single intravitreal injection of ADVM-022 gene therapy candidate in patients with diabetic macular edema (DME), the leading cause of vision loss among patients with diabetic retinopathy (DR).

Learn More